These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32339417)

  • 1. Fibrinolysis and tranexamic acid: mechanistic principles.
    Draxler DF; Medcalf RL
    ANZ J Surg; 2020 Apr; 90(4):410-411. PubMed ID: 32339417
    [No Abstract]   [Full Text] [Related]  

  • 2. Tranexamic acid in patients with multiple injuries: good, elegant, and cheap?
    Egea-Guerrero JJ; Ballesteros MÁ; Quintana-Díaz M
    Emergencias; 2019 Ago; 31(4):281-282. PubMed ID: 31347809
    [No Abstract]   [Full Text] [Related]  

  • 3. Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner.
    Barrett CD; Moore HB; Kong YW; Chapman MP; Sriram G; Lim D; Moore EE; Yaffe MB
    J Trauma Acute Care Surg; 2019 Jan; 86(1):101-107. PubMed ID: 30575685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basis of antifibrinolytic therapy.
    Prentice CR
    J Clin Pathol Suppl (R Coll Pathol); 1980; 14():35-40. PubMed ID: 6159375
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical relevance and practical assessment of fibrinolysis shutdown.
    Moore HB; Moore BA; Sauaia A; Moore EE
    ANZ J Surg; 2020 Apr; 90(4):413-414. PubMed ID: 31535453
    [No Abstract]   [Full Text] [Related]  

  • 6. Perspectives on tranexamic acid in surgery.
    Balogh ZJ; King KL
    ANZ J Surg; 2020 Apr; 90(4):409. PubMed ID: 32339435
    [No Abstract]   [Full Text] [Related]  

  • 7. Postinjury fibrinolysis shutdown: Rationale for selective tranexamic acid.
    Moore EE; Moore HB; Gonzalez E; Chapman MP; Hansen KC; Sauaia A; Silliman CC; Banerjee A
    J Trauma Acute Care Surg; 2015 Jun; 78(6 Suppl 1):S65-9. PubMed ID: 26002266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trials and Cochrane analyses versus precision-based medicine for tranexamic acid and viscoelastic testing in trauma.
    Walsh M; Grisoli A; Zackariya N; Thomas AV; Sualeh A
    ANZ J Surg; 2020 Apr; 90(4):415-416. PubMed ID: 32339433
    [No Abstract]   [Full Text] [Related]  

  • 9. Improved platelet counts during prolonged tranexamic therapy for Quebec platelet disorder implicate the underlying fibrinolytic defect as the cause of lower platelet counts.
    Hayward CPM; Tasneem S; Rivard GE
    Int J Lab Hematol; 2020 Dec; 42(6):e274-e276. PubMed ID: 33205919
    [No Abstract]   [Full Text] [Related]  

  • 10. Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates.
    He S; Johnsson H; Zabczyk M; Hultenby K; Wallén H; Blombäck M
    Thromb Haemost; 2014 Mar; 111(3):417-28. PubMed ID: 24196490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational model of tranexamic acid on urokinase mediated fibrinolysis.
    Wu TB; Orfeo T; Moore HB; Sumislawski JJ; Cohen MJ; Petzold LR
    PLoS One; 2020; 15(5):e0233640. PubMed ID: 32453766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tranexamic acid--an old drug in a new costume. Multinational studies and new texts provide a boost for the antifibrinolytic agent].
    Tengborn L; Berntorp E
    Lakartidningen; 2013 Aug 21-Sep 3; 110(34-35):1458-9. PubMed ID: 24044180
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of fibrinogen in massive injury.
    Maung AA; Kaplan LJ
    Minerva Anestesiol; 2014 Jan; 80(1):89-95. PubMed ID: 23857437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous small-dose tranexamic acid reduces fibrinolysis but not transfusion requirements during orthotopic liver transplantation.
    Kaspar M; Ramsay MA; Nguyen AT; Cogswell M; Hurst G; Ramsay KJ
    Anesth Analg; 1997 Aug; 85(2):281-5. PubMed ID: 9249100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does Oral or Topical Tranexamic Acid Control Bleeding From Epistaxis?
    Bridwell RE; April MD; Long B
    Ann Emerg Med; 2019 Aug; 74(2):300-302. PubMed ID: 31060746
    [No Abstract]   [Full Text] [Related]  

  • 16. TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial.
    Ducloy-Bouthors AS; Jeanpierre E; Saidi I; Baptiste AS; Simon E; Lannoy D; Duhamel A; Allorge D; Susen S; Hennart B
    Trials; 2018 Mar; 19(1):149. PubMed ID: 29490690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled trial.
    Bouthors AS; Hennart B; Jeanpierre E; Baptiste AS; Saidi I; Simon E; Lannoy D; Duhamel A; Allorge D; Susen S
    Trials; 2018 Mar; 19(1):148. PubMed ID: 29490682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporally and regionally disparate differences in plasmin activity by tranexamic acid.
    Reust DL; Reeves ST; Abernathy JH; Dixon JA; Gaillard WF; Mukherjee R; Koval CN; Stroud RE; Spinale FG
    Anesth Analg; 2010 Mar; 110(3):694-701. PubMed ID: 20185649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical use of synthetic antifibrinolytic agents during liver transplantation.
    Kang Y
    Semin Thromb Hemost; 1993; 19(3):258-61. PubMed ID: 8362255
    [No Abstract]   [Full Text] [Related]  

  • 20. Antifibrinolytic agents in traumatic hemorrhage: a large scale randomized controlled trial is needed.
    Coats T; Hunt B; Roberts I; Shakur H
    Croat Med J; 2005 Feb; 46(1):146-7. PubMed ID: 15744922
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.